......my post about my thoughts on Insmed/Roche/PUMA was deleted twice today. Since there must not be anything of interest there, I apologize for wasting the space of this board. Hope everyone is doing well.
This is a little off-topic from Arikayce, but it is something that made me think.
With all of the talk about PUMA yesterday/today, I read terms like breast cancer,
Roche, Herceptin, and it got things rolling around my head. So, I looked
back into the Insmed archives and found the following information from 2003.
As much as I dislike Roche/Genentech (LOL) might they be interested in
relationship with Insmed (separate from iPlex)).....again, LOL
RICHMOND, Va.--(BUSINESS WIRE)--Dec. 3, 2003--Insmed Incorporated (Nasdaq-NMS: INSM) (Nasdaq: INSM) reported today that data from recent studies of the Company's proprietary anti-cancer compound, recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3), will be presented at The 26th Annual San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzalez Convention Center, San Antonio, Texas, December 3 - 6.
These studies conducted in the laboratory of Dr. Brian Leyland-Jones of McGill University were designed to explore the ability of rhIGFBP-3 to sensitize breast cancer cells to Herceptin® (Trastuzumab).
The results of this study, published in the abstract titled, "Recombinant human insulin-like growth factor binding protein-3 (rhIGFBP-3) as a potential therapeutic agent for the treatment of Herceptin-resistant breast cancer", demonstrated the following:
1. In Herceptin resistant breast carcinoma cells there was an increased level of insulin-like growth factor receptor.
2. rhIGFBP-3 caused dose dependent inhibition of Herceptin resistant breast carcinoma growth.
3. rhIGFBP-3 in combination with Herceptin caused a dose dependent increase in sensitivity of breast carcinoma cells to Herceptin.
For reprints, please contact, Baxter Phillips, at 804.565.3041 or email@example.com